看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
1 `' c) e- f; u8 V/ B# p- N; n ~( v
: z6 \7 l0 J- _( `9 X2 }' O8 ]& UCurrently available feasibility data for possible combination strategies. 2 c+ J4 x; A& ?0 W8 \% x2 ~
————————————————————————————————
' \7 S* @: V. bCombination Feasibility according to preliminary data
, ~0 N' s5 f) T# \3 ^——————————————————————————————————
( e6 D/ |: c, H( Z% u q% L" Q4 ]Bevacizumab + sorafenib Yes, reduced dose
4 z! z0 K! A0 U6 `9 P- gBevacizumab + sunitinib† No # T: O5 {/ O1 n- }! ^) j
Bevacizumab + temsirolimus Yes
: C4 @' }2 v/ p, e! tBevacizumab + everolimus Yes * e# h% C! \3 V( |9 S
Sorafenib + sunitinib ?
. k% a/ |! M8 C3 ]1 o: c3 SSorafenib + temsirolimus Yes, reduced dose
1 i N% {. \% {) |Sorafenib + everolimus Yes, reduced dose
u( ~3 N2 L" zSunitinib + temsirolimus† No ; e- C' n- H; x* D% D0 G! j. z
Sunitinib + everolimus ? " {" o9 g7 ]( y8 M- q V; j7 C
Temsirolimus + everolimus ?
: P6 D6 ^1 R$ n& c1 W————————————————————0 K! ?; O$ d, R# ]- ?) \' d6 U: a' s
†Led to US FDA warning.
' ~5 X l# G% r; Y+ s& I?: As yet unattempted combination." B/ E. D4 w+ E" _* u# f
|
显身卡
